> Disorders > Neoplastic Process > Endometrial Carcinoma

Endometrial Carcinoma

Endometrial Carcinoma is a type of uterine cancer that originates in the lining of the uterus (the endometrium).
It is one of the most common gynecological cancers, with a high incidence rate.
This malignant neoplasm can present with abnormal vaginal bleeding, pelvic pain, and other symptoms.
Accurate diagnosis and effective treatment are crucial for managing Endometrial Carcinoma and improving patient outcomes.
Resaerch in this area is vital for advancing our understanding and improving clinical care.

Most cited protocols related to «Endometrial Carcinoma»

Pan-Cancer Transcriptomic and Proteomic Analysis

Cited 94 times

Results are based in part upon data generated by TCGA Research Network (http://cancergenome.nih.gov/). We aggregated TCGA transcriptomic and RPPA data from public repositories, listed in the “Data availability” section. RNA-seq expression data were processed by TCGA at the gene level, rather than at the transcript level. Tumors spanned 32 different TCGA projects, each project representing a specific cancer type, listed as follows: LAML, acute myeloid leukemia; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; LGG, lower grade glioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CRC, colorectal adenocarcinoma (combining COAD and READ projects); ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. Cancer molecular profiling data were generated through informed consent as part of previously published studies and analyzed per each original study’s data use guidelines and restrictions.

Chen F., Chandrashekar D.S., Varambally S, & Creighton C.J. (2019). Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature Communications, 10, 5679.

Publication 2019

4-carboxyphenylglyoxal Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cholangiocarcinoma Chromophobia Chronic Obstructive Airway Disease Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Profiling Genes Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Lung Lymph Malignant Neoplasms Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Pheochromocytoma Prostate Renal Cell Carcinoma RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma X-Ray Photoelectron Spectroscopy

Multi-cancer Proteomic Profiling from CPTAC

Cited 50 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2022

Adenocarcinoma of Lung Brain Neoplasm, Malignant Cancer of Colon Endometrial Carcinoma Hypernephroid Carcinomas Malignant Neoplasm of Breast Mass Spectrometry Neoplasms Ovarian Cancer Proteins

Comprehensive Genomic Profiling of Cancer Samples

Cited 39 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019

Adenocarcinoma Carcinoma Clinical Laboratory Services Duodenum Endometrial Carcinoma Endometrium Esophagogastric Junction Ethics Committees, Research Exons Gene, Cancer Genes HapMap Hybrids Malignant Neoplasms Mutation Neoplasms Oncogenes Pathologists Patients Pharmaceutical Preparations Tissues TMB 6

Endometrial Cancer Proteomics and Transcriptomics

Cited 28 times

Duke University Medical Center and the Gynecologic Oncology Group provided fresh frozen endometrial cancer tissue specimens from 91 stage I endometrial patients, under IRB-approved protocols at the corresponding institutions. Endometrial tissue specimens harvested by pathologists at the time of surgery were frozen until the time of the analysis. Hematoxylin and eosin (H&E) stained tissue specimens were evaluated by one of two board certified gynecologic pathologists to confirm the diagnosis. Seven age-matched normal endometrial samples from post-menopausal women comprised the control sample set.
Proteomic spectral count data on the same samples originated from Orbitrap and FT-ICR mass spectrometers. Details of the sample preparation, instrumentation, and spectral identifications are in Maxwell et al[14 ]. The gene expression data were from Affymetrix U133 Plus 2.0 microarrays. The raw data.cel and.chp files have been submitted to GEO in a MIAME compliant format (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bhmrrwmyyqsoeba&acc=GSE17025) and will be released July 8, 2011.

Day R.S., McDade K.K., Chandran U.R., Lisovich A., Conrads T.P., Hood B.L., Kolli V.K., Kirchner D., Litzi T, & Maxwell G.L. (2011). Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinformatics, 12, 213.

Publication 2011

Diagnosis Endometrial Carcinoma Endometrium Eosin Freezing Gene Expression Hematoxylin Microarray Analysis Neoplasms Pathologists Patients Postmenopause Tissues Tissue Stains Woman

European Ancestry Endometrial Cancer GWAS

Cited 25 times

Analyses were based on 13 studies of endometrial cancer, of which four studies contributed case samples to more than one genotyping project. Data were also included from the E2C2 consortium of 45 separate studies. All participants were of European ancestry. Data from the E2C2 genome-wide association studies (GWAS) and from the ANECS, SEARCH, NSECG GWASs and the iCOGS project have been previously published, and are described in de Vivo et al.^{33 (link)} and Cheng et al.^{6 (link)}, respectively.

O’Mara T.A., Glubb D.M., Amant F., Annibali D., Ashton K., Attia J., Auer P.L., Beckmann M.W., Black A., Bolla M.K., Brauch H., Brenner H., Brinton L., Buchanan D.D., Burwinkel B., Chang-Claude J., Chanock S.J., Chen C., Chen M.M., Cheng T.H., Clarke C.L., Clendenning M., Cook L.S., Couch F.J., Cox A., Crous-Bous M., Czene K., Day F., Dennis J., Depreeuw J., Doherty J.A., Dörk T., Dowdy S.C., Dürst M., Ekici A.B., Fasching P.A., Fridley B.L., Friedenreich C.M., Fritschi L., Fung J., García-Closas M., Gaudet M.M., Giles G.G., Goode E.L., Gorman M., Haiman C.A., Hall P., Hankison S.E., Healey C.S., Hein A., Hillemanns P., Hodgson S., Hoivik E.A., Holliday E.G., Hopper J.L., Hunter D.J., Jones A., Krakstad C., Kristensen V.N., Lambrechts D., Marchand L.L., Liang X., Lindblom A., Lissowska J., Long J., Lu L., Magliocco A.M., Martin L., McEvoy M., Meindl A., Michailidou K., Milne R.L., Mints M., Montgomery G.W., Nassir R., Olsson H., Orlow I., Otton G., Palles C., Perry J.R., Peto J., Pooler L., Prescott J., Proietto T., Rebbeck T.R., Risch H.A., Rogers P.A., Rübner M., Runnebaum I., Sacerdote C., Sarto G.E., Schumacher F., Scott R.J., Setiawan V.W., Shah M., Sheng X., Shu X.O., Southey M.C., Swerdlow A.J., Tham E., Trovik J., Turman C., Tyrer J.P., Vachon C., VanDen Berg D., Vanderstichele A., Wang Z., Webb P.M., Wentzensen N., Werner H.M., Winham S.J., Wolk A., Xia L., Xiang Y.B., Yang H.P., Yu H., Zheng W., Pharoah P.D., Dunning A.M., Kraft P., De Vivo I., Tomlinson I., Easton D.F., Spurdle A.B, & Thompson D.J. (2018). Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 9, 3166.

Publication 2018

Endometrial Carcinoma Europeans Genome-Wide Association Study

Most recents protocols related to «Endometrial Carcinoma»

ADRA2A Expression in Endometrial Cancer

The ENCORI database (https://starbase.sysu.edu.cn/index.php) was used to detect ADRA2A expression in endometrial cancer tissues. The SwissTargetPrediction webtool (http://www.swisstargetprediction.ch/) predicted the interaction between PD and ADRA2A.

Ni Z., Dawa Z., Suolang D., Pingcuo Q., Langga Z., Quzhen P, & Deji Z. (2023). Platycodin D inhibits the proliferation, invasion and migration of endometrial cancer cells by blocking the PI3K/Akt signaling pathway via ADRA2A upregulation. Oncology Letters, 25(4), 136.

Publication 2023

ADRA2A protein, human Endometrial Carcinoma Tissues

Adjuvant Therapy for Residual Endometrial Cancer

1. Patients with residual tumors, whether measurable or non-measurable after surgery
2. Endometrioid adenocarcinoma combined with other histological types
3. Non-endometrial carcinoma, for example, serous carcinoma, clear cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, or uterine sarcoma (including carcinosarcoma)
4. An interval between the operation and the start of adjuvant therapy exceeding 8 weeks
5. Previous pelvic radiotherapy
6. Previous history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
7. History of myocardial infarction, stroke, unstable angina, decompensated heart failure, or deep vein thrombosis
8. Impaired renal or cardiac function.
9. Known intolerance to intervention therapy or any excipients
10. Known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study.

Li Y., Zhu C., Xie H., Chen Y., Lv W., Xie X, & Wang X. (2023). Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of Gynecologic Oncology, 34(2), e37.

Publication 2023

Adenocarcinoma, Clear Cell Adenocarcinoma, Endometrioid Angina, Unstable Carcinoma, Neuroendocrine Carcinosarcoma Cerebrovascular Accident Congestive Heart Failure Endometrial Carcinoma Heart Kidney Malignant Neoplasms Myocardial Infarction Neoplasms, Second Primary Patients Pelvis Pharmaceutical Adjuvants Residual Tumor Sarcoma Serous Cystadenocarcinoma Substance Abuse Therapeutics Undifferentiated Carcinoma Uterus Veins

Personalized Endometrial Cancer Treatment

The primary objective of this study is to compare the adjuvant treatment efficacy in women with IR (stage IA grade 3 or stage IB grade 1–2) or HIR (stage IB grade 3 or stage II) endometrioid endometrial cancer (EEC) treated after surgery with molecular profile-based recommendations for either observation, or chemoradiotherapy or radiotherapy. We hypothesise that the efficacy of molecular-based treatment is not inferior to that of conventional clinicopathological-based treatment.
The secondary objective is to determine the preferred treatment for each subgroup following different recommendations with regard to the treatment efficacy, safety and tolerability. We hypothesise that de-escalated treatment strategies yield better quality-of-life outcomes without sacrificing treatment efficacy in patients with POLE mutation (POLEmut) and partial mismatch repair deficient (MMRd) or non-specific molecular profile (NSMP) subgroups. In contrast, escalated treatment is considered necessary for the p53-abnormal (p53abn) subgroup.

Publication 2023

Chemoradiotherapy Endometrial Carcinoma Mismatch Repair Mutation Operative Surgical Procedures Patients Pharmaceutical Adjuvants Radiotherapy Safety Woman

Endometrial Cancer Cell Response to MLN4924

Human endometrial cancer cell lines Ishikawa and HEC-1-A were purchased from ATCC and cultured in 10% Gibco fetal bovine serum and 1% penicillin-streptomycin solution at 37°C with 5% CO2. MLN4924 powder was diluted with DMSO to prepare a 10mM storage solution for storage. The medium containing 0μM, 0.25μM, 0.5μM, 1.0μM MLN4924 was configured. The Ishikawa and HEC-1-A cells were seeded in triplicate into 96-well plates at 1×103 cells/well, then treated with different medium concentrations. Cell proliferation was determined by Cell Counting Kit-8 assay (Dojindo, Kumamoto, Japan) and ATP-Lite kit (PerkinElmer, Turku, Finland) according to the manufacturer’s instructions.

Li Y., Niu J.H, & Wang Y. (2023). Machine learning-based neddylation landscape indicates different prognosis and immune microenvironment in endometrial cancer. Frontiers in Oncology, 13, 1084523.

Publication 2023

Biological Assay Cell Lines Cell Proliferation Cells Endometrial Carcinoma Fetal Bovine Serum Homo sapiens MLN4924 Penicillins Powder Streptomycin Sulfoxide, Dimethyl

Identifying Lung Cancer Recurrence Algorithm

The algorithm was constructed similarly to the previously developed algorithms to identify cancer recurrence from malignant melanoma, bladder, breast, and endometrial cancer by Rasmussen et al13–16 (link) (Figure 1). The end date of primary lung cancer treatment was defined as the date of lung cancer surgery or the date of the last chemotherapy procedure code in case of adjuvant chemotherapy. A subsequent period with no register-based evidence of ongoing malignant disease was required to prevent inclusion of patients with residual disease after completed lung cancer treatment. The final day of this period was 90 days after surgery or 30 days after ended adjuvant chemotherapy treatment, whichever came last. Indicators of ongoing disease was 1) malignant morphology (SNOMED codes M8* and M9*), 2) new diagnosis codes indicating malignant disease (ICD-10: C00*- C96* and D37*-D48*excluding C44* (non-melanoma skin cancer) and C34* (lung cancer)), 3) procedure codes for radiotherapy (BWGC*) or chemotherapy (BWHA*) combined with a malignant diagnosis code (ICD-10: C00*-C96* and D37*-D48*), and 4) UICC stage IV.
Figure 1

Schematic overview of the algorithm.

After the period with no register-based evidence of ongoing malignant disease, the algorithm searched for indicators of cancer recurrence (Figure 1). A patient was defined as being diagnosed with lung cancer recurrence if one of the following six indicators was present:

ICD-10: C349X (lung cancer recurrence diagnosis);

ICD-10: C76*-C79* or C34xM (metastasis diagnosis) and no new primary cancer registered after the conclusion of primary lung cancer treatment;

SNOMED morphology codes M8*-M9* and 7 (malignant recurrence) in the fifth digit;

SNOMED morphology codes M8*-M9* and 4 (direct spread to surrounding tissue) or 6 (malignant metastasis) in the fifth digit and a morphology similar to a morphology code registered within 90 days of the primary lung cancer diagnosis date or date of lung cancer surgery;

Radiotherapy or chemotherapy procedure codes combined with a diagnosis code indicating lung cancer (ICD-10: C34*);

Radiotherapy or chemotherapy procedure codes combined with a diagnosis code indicating metastases (ICD-10: C76*-C79* or C34xM) and no new primary cancer registered after the conclusion of primary lung cancer treatment.

Indicators of recurrence were disregarded if they appeared after ended follow-up in the gold standard. The recurrence date estimated by the algorithm was defined as the first date with a registration of an indicator of recurrence.

Rasmussen L.A., Christensen N.L., Winther-Larsen A., Dalton S.O., Virgilsen L.F., Jensen H, & Vedsted P. (2023). A Validated Register-Based Algorithm to Identify Patients Diagnosed with Recurrence of Surgically Treated Stage I Lung Cancer in Denmark. Clinical Epidemiology, 15, 251-261.

Publication 2023

Breast Chemotherapy, Adjuvant Diagnosis Endometrial Carcinoma Familial Atypical Mole-Malignant Melanoma Syndrome Gold Lung Cancer Lung Diseases Malignant Neoplasms Melanoma Menstruation Disturbances Neoplasm Metastasis Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy Recurrence Residual Cancer Residual Tumor Tissues Urinary Bladder

Top products related to «Endometrial Carcinoma»

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Hec 1a by American Type Culture Collection

Sourced in United States, China, United Kingdom

The HEC-1A is a laboratory equipment product offered by the American Type Culture Collection (ATCC). It is a cell culture incubator designed for maintaining optimal conditions for the growth and maintenance of cell lines. The HEC-1A provides temperature, humidity, and CO2 control to create an environment suitable for culturing a variety of cell types.

Rl95 2 by American Type Culture Collection

Sourced in United States

The RL95-2 is a cell line derived from human endometrial carcinoma. It is a widely used in vitro model for the study of endometrial cancer. The RL95-2 cell line maintains characteristics of well-differentiated endometrial adenocarcinoma and is commonly utilized for research purposes.

Penicillin streptomycin by Thermo Fisher Scientific

Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia

Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

Hec 1b by American Type Culture Collection

Sourced in United States, China

The HEC-1B is a laboratory equipment used for cell culture applications. It is a high-efficiency cell culture incubator that provides a controlled environment for the growth and maintenance of cells.

Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica

DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.

Streptomycin by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama

Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.

Dmem f12 by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Denmark, Israel, Macao, Ireland, Netherlands, Austria, Hungary, Holy See (Vatican City State), Sweden, Brazil, Argentina, India, Poland, Morocco, Czechia

DMEM/F12 is a cell culture medium developed by Thermo Fisher Scientific. It is a balanced salt solution that provides nutrients and growth factors essential for the cultivation of a variety of cell types, including adherent and suspension cells. The medium is formulated to support the proliferation and maintenance of cells in vitro.

An3ca by American Type Culture Collection

Sourced in United States, China

The AN3CA is a piece of laboratory equipment designed for cell culture applications. It is a cell culture flask that provides a controlled environment for the growth and maintenance of cell lines. The core function of the AN3CA is to support the cultivation of cells in vitro.

Penicillin by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco

Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.

What are the common symptoms of Endometrial Carcinoma?

The most common symptoms of Endometrial Carcinoma include abnormal vaginal bleeding, such as bleeding between periods or after menopause, as well as pelvic pain or discomfort. Some patients may also experience unexplained weight loss, fatigue, and changes in bowel or bladder habits. It's important to report any unusual symptoms to your healthcare provider for prompt evaluation and diagnosis.

How is Endometrial Carcinoma diagnosed?

Endometrial Carcinoma is typically diagnosed through a combination of tests, including a pelvic exam, transvaginal ultrasound, and endometrial biopsy. The biopsy, where a small sample of the uterine lining is taken for analysis, is the most accurate way to confirm the diagnosis. In some cases, additional imaging tests, such as CT or MRI scans, may be ordered to determine the extent of the cancer and help with treatment planning.

What are the different types of Endometrial Carcinoma?

There are several different types of Endometrial Carcinoma, each with its own characteristics and treatment approach. The most common type is endometriod carcinoma, which accounts for about 80% of cases. Other less common types include serous carcinoma, clear cell carcinoma, and carcinosarcoma. Each type has unique features, such as the appearance of the cancer cells and their aggressiveness, which can impact the prognosis and optimal treatment strategy.

How can PubCompare.ai assist with Endometrial Carcinoma research?

PubCompare.ai can be a valuable tool for researchers studying Endometrial Carcinoma. The platform allows you to efficiently screen the literature for relevant protocols, leveraging AI to pinpoint critical insights. This can help you identify the most effective protocols related to Endometrial Carcinoma for your specific research goals. The platfrm's AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accuracy, ultimately advancing your Endometrial Carcinoma research.

How can PubCompare.ai improve the quality of Endometrial Carcinoma research?

By using PubCompare.ai, researchers can improve the quality and impact of their Endometrial Carcinoma studies. The platform's AI-powered comparisons help identify the most effective protocols, ensuring that your research is based on the best available methods. This leads to more reproducible and accurate results, which is crucial for advancing our understanding of Endometrial Carcinoma and developing more effective treatments. PubCompare.ai's cutting-edge technology can be a game-changer for Endometrial Carcinoma research, enhancing the reliability and impact of your work.

More about "Endometrial Carcinoma"

Endometrial Carcinoma, also known as Uterine Cancer or Endometrial Cancer, is a type of malignant neoplasm that originates in the lining of the uterus, the endometrium.
As one of the most common gynecological cancers, it has a high incidence rate and can present with various symptoms such as abnormal vaginal bleeding, pelvic pain, and other related issues.
Accurate diagnosis and effective treatment are crucial for managing Endometrial Carcinoma and improving patient outcomes.
Research in this area is vital for advancing our understanding and improving clinical care.
Key subtopics include the use of cell lines like FBS, HEC-1A, RL95-2, HEC-1B, AN3CA, and media such as DMEM and DMEM/F12, as well as the application of antibiotics like Penicillin and Streptomycin in Endometrial Carcinoma research.
Utilizing the latest advancements in technology, AI-driven tools like PubCompare.ai can optimize Endometrial Carcinoma research by enhancing reproducibility and accuracy.
This innovative platform helps users locate protocols from literature, pre-prints, and patents, while providing AI-powered comparisons to identify the best protocols and products, ultimately improving the overall research process and patient care.